

**Supplementary Table S5: Pre-therapeutic samples from neoadjuvant treated TNBC**

| Dataset            | Institution   | Chemotherapy  | TNBC | pCR (%)   |
|--------------------|---|---|------|-----------|
| MDA133             | MDACC, Houston, TX                                    | TFAC  | 36   | 18 (50.0) |
| Frankfurt-3        | University of Frankfurt                               | TAC or TAC-NX   | 19   | 4 (21.1)  |
| GSE18728           | University of Washington/Seattle Cancer Care Alliance | Docetaxel/Capecitabine                                    | 8    | 3 (37.5)  |
| GSE19697           | Washington University School of Medicine St. Louis    | E-Doc   | 24   | 5 (20.8)  |
| GSE20194           | MDACC, Houston, TX                                    | paclitaxel, 5-fluorouracil, cyclophosphamide, doxorubicin | 50   | 11 (22.0) |
| GSE20271           | MDACC, Houston, TX                                    | paclitaxel, 5-fluorouracil, cyclophosphamide, doxorubicin | 54   | 11 (20.4) |
| Total              |   |   | 191  | 52 (27.2) |
| <b>Validation:</b> |   |   |      |           |
| GSE16446           | TOP-Trial; Institut Jules Bordet, Brussels            | Epirubicin Mono   | 95   | 52 (27.2) |